Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-05-31Clinical Trial Update: Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis [Phase 1]
Phase 1 clinical trial results for ANK-700 in relapsing-remitting multiple sclerosis have been posted.
-
CLINICAL_TRIALS trial_result · 2025-05-02Clinical Trial Update: Administration of Fingolimod in Greek Patients With Multiple Sclerosis.
Clinical trial update indicates Fingolimod is to be administered in Greek patients with Relapsing Remitting Multiple Sclerosis, with the stu…
-
CLINICAL_TRIALS trial_result · 2025-04-20Clinical Trial Update: COMparison Between All immunoTherapies for Multiple Sclerosis.
A completed clinical trial led by Karolinska Institutet comparing all immunotherapies for relapsing-remitting multiple sclerosis has posted …
-
CLINICAL_TRIALS trial_result · 2025-04-11Clinical Trial Update: Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment
A clinical trial update reports reduced oligodendrocyte-specific cytotoxicity observed with Ofatumumab treatment in Relapsing Remitting Mult…
-
CLINICAL_TRIALS trial_result · 2025-03-27Clinical Trial Update: A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients
Completed clinical-trial update examining real-world adherence to and outcomes of patients with relapsing-remitting multiple sclerosis treat…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue Study [NA]
A clinical trial evaluating dietary approaches to treat fatigue in multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-06Clinical Trial Update: Observational Study of Persistence on Bafiertam Treatment in Routine Clinical Practice
An observational study assessing persistence on Bafiertam (dimethyl fumarate) in relapsing-remitting multiple sclerosis has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: PET with [18F]Flumazenil As an Index of Neurodegeneration in MS [NA]
The document notes completion of a clinical trial evaluating PET imaging with the radiotracer [18F]Flumazenil as an index of neurodegenerati…
-
CLINICAL_TRIALS trial_result · 2025-02-27Clinical Trial Update: Melatonin in Patients With Multiple Sclerosis (MS). [EARLY_Phase 1]
An early-phase study evaluating melatonin in relapsing-remitting multiple sclerosis has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2025-02-17Clinical Trial Update: Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis [Phase 4]
Phase 4 trial results assess the effects of ocrelizumab on B-cell tolerance defects in relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2025-02-06Clinical Trial Update: The Effect of Metformin As an Adjuvant Therapy on Immunological Parameters in Egyptian Patients with RRMS: a Pilot Study [Phase 2]
A Phase 2 pilot trial evaluated metformin as an adjuvant therapy in relapsing-remitting multiple sclerosis patients in Egypt, focusing on im…
-
CLINICAL_TRIALS trial_result · 2025-01-22Clinical Trial Update: Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy [Phase 3]
A Phase 3 safety study evaluating immune responses to vaccines in relapsing forms of multiple sclerosis in participants receiving ozanimod v…
-
CLINICAL_TRIALS trial_result · 2025-01-15Clinical Trial Update: Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 3]
This Phase 3 study evaluates the effectiveness and safety of ocrelizumab in people with early-stage relapsing-remitting multiple sclerosis; …
-
CLINICAL_TRIALS trial_result · 2025-01-07Clinical Trial Update: the Effect of Reiki Application on Depression, Anxiety and Physical Activity in Patient With Multiple Sclerosis [NA]
A completed clinical trial evaluated Reiki therapy for depression, anxiety, and physical activity in Relapsing-remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2024-12-18Clinical Trial Update: Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)
A clinical trial update reports the effectiveness of cladribine tablets in participants with highly-active relapsing multiple sclerosis (CAM…
-
CLINICAL_TRIALS trial_result · 2024-12-03Clinical Trial Update: Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS [Phase 1, Phase 2]
This trial update reports on the safety, tolerability, and preliminary efficacy of monthly long-acting glatiramer acetate depot injections (…
-
CLINICAL_TRIALS trial_result · 2024-11-08Clinical Trial Update: A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis [Phase 2]
This clinical trial update reports results from a Phase 2 study of ocrelizumab in children and adolescents with relapsing-remitting multiple…
-
CLINICAL_TRIALS trial_result · 2024-10-28Clinical Trial Update: Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
A completed clinical trial evaluating upper-extremity function in advanced multiple sclerosis patients treated with ocrelizumab (Ocrevus) an…
-
CLINICAL_TRIALS trial_result · 2024-10-01Clinical Trial Update: Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis [Phase 2]
A Phase 2 clinical study evaluating the long-term safety, tolerability, and efficacy of ponesimod in relapsing-remitting multiple sclerosis …
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab
Clinical trial evaluating the safety and efficacy of switching relapsing-remitting multiple sclerosis patients from natalizumab to ocrelizum…
-
CLINICAL_TRIALS trial_result · 2024-08-23Clinical Trial Update: Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt
A completed clinical trial evaluated the safety and effectiveness of the generic fingolimod brand Sphingomod in patients with relapsing-remi…
-
CLINICAL_TRIALS trial_result · 2024-08-13Clinical Trial Update: A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS [Phase 3]
A Phase IIIb multicenter international trial evaluating EK-12 for Relapsing-Remitting Multiple Sclerosis has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-07-29Clinical Trial Update: Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies
A completed study evaluating changes in immunoglobulin levels in patients with relapsing multiple sclerosis treated with anti-CD20 therapies…
-
CLINICAL_TRIALS trial_result · 2024-06-21Clinical Trial Update: A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) [Phase 4]
The Phase 4 trial evaluating the radiological onset of action after starting subcutaneous natalizumab in relapsing-remitting multiple sclero…
-
CLINICAL_TRIALS trial_result · 2024-06-12Clinical Trial Update: A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration [Phase 3]
Phase 3 trial evaluating extended-interval dosing of natalizumab in relapsing-remitting multiple sclerosis patients switching from standard …